NPM1 MRD
NPM1 MRD-994
NPM1 MRD
994
LAB994
MSO
NPM1 minimal residual
Minimal residual disease levels assessed by NPM1 mutation
Minimal residual disease levels assessed by NPM1 mutation
- To track and identify previously detected NPM1 mutations in post treatment follow up samples, a multiplex master mix targeting exon 12 on the NPM1 gene is used to amplify DNA extracted from a patient sample.
- Identify tumor-specific markers for post-treatment monitoring.
- Monitor and evaluate disease recurrence.
EDTA whole blood
5.0 mL
Immediatley following collection, mix sample by inverting 8 - 10 times to prevent clotting
Do not spin
Lavender (EDTA), 4mL
ACD-A whole blood
EDTA bone marrow
ACD-A bone marrow
EDTA bone marrow
ACD-A bone marrow
Bone marrow: 3 mL
Immediatley following collection, mix sample by inverting 8 - 10 times to prevent clotting
Do not spin
ACD-A whole blood:
Yellow ACD-A
Bone marrow:
Lavender (EDTA), 4mL
Yellow ACD-A
Refrigerated (preferred) - 7 days
Ambient - 72 hours
Frozen - NO
Laboratories for Personalized Molecular Medicine (LabPMM) LLC (NMP1 MRD NGS Assay): R-NX
7 - 14 days
Next-Generation Sequencing (NGS)
An interpretive report will be issued
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
0049U
03/25/2019
03/05/2024
03/05/2024